Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of Intravenous Anifrolumab in Adults with Active Systemic Lupus Erythematosus
2016-000625-39Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Anifrolumab continuation arm with Placebo arm (2 arms). Primary endpoints: Rates of adverse events of special interest and Rates of serious adverse events. Started Jun 2016; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2016-000625-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000625-39.